Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Trial to Examine Effectiveness of a Human Allograft for Treatment of DFU and VLU

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03999281
Recruitment Status : Completed
First Posted : June 26, 2019
Last Update Posted : June 28, 2019
Sponsor:
Information provided by (Responsible Party):
Solsys Medical LLC

Brief Summary:
Retrospective clinical study of 188 patients to examine effectiveness of human cryopreserved allograft in the treatment of diabetic foot ulcers and venous leg ulcers

Condition or disease Intervention/treatment
Determine Effectiveness of Theraskin in the Treatment of DFU and VLU Other: Human Allograft (Theraskin)

Detailed Description:
Retrospective Observational study of 188 consecutive patients to examine the efficacy of biologically active cryopreserved human skin allograft (Theraskin) on the treatment of diabetic foot ulcers and venous leg ulcers

Layout table for study information
Study Type : Observational
Actual Enrollment : 188 participants
Observational Model: Case-Control
Time Perspective: Retrospective
Official Title: Retrospective Clinical Trial Study of 188 Consecutive Patients to Examine the Effectiveness of a Biological Active Cryopreserved Human Skin Allograft on the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers
Actual Study Start Date : March 20, 2003
Actual Primary Completion Date : September 20, 2009
Actual Study Completion Date : September 20, 2009

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Diabetic Foot Ulcers (DFU)
Study began with 214 consecutive patient; After excluding patients who did not meet the study criteria, the final eligible cohort consisted of 188 subjects, with 54 with diabetic foot ulcers
Other: Human Allograft (Theraskin)
Biologically active cryopreserved human skin allograft (Theraskin) was used on both cohorts, both diabetic foot ulcer and venous leg ulcer.

Venous Leg Ulcer (VLU)
Study began with 214 consecutive patient; After excluding patients who did not meet the study criteria, the final eligible cohort consisted of 188 subjects, with 134 venous leg ulcers.
Other: Human Allograft (Theraskin)
Biologically active cryopreserved human skin allograft (Theraskin) was used on both cohorts, both diabetic foot ulcer and venous leg ulcer.




Primary Outcome Measures :
  1. Primary aim was to determine effectiveness of Theraskin together with standard of care [ Time Frame: 12-20 weeks ]
    Theraskin used together with standard of care in healing DFU and VLU wounds


Secondary Outcome Measures :
  1. Measure of effectiveness based on healing [ Time Frame: 12-20 weeks ]
    Effectiveness was measured based on the proportion of complete wound closures at 12 and 20 weeks



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population

Population included ages 18- any age, males 50.5 % and females 49.5%, There was more males in the diabetic subset and more females in the venous subset.

Percentage by Race: White: 72.3, Black: 17.6, Hispanic: 4.8 and unknown: 5.3

Criteria

Inclusion Criteria:

  1. Theraskin applied to lower extremity wound during the study period.
  2. Over 18 years of age.
  3. Males and Females.
  4. lower Extremity wound due to diabetic neuropathy or venous insufficiency.
  5. Documented palpable pedal pulse (dorsalis pedis and/or posterior tibialis arteries and/or palpable bypass graft), or ankle brachial index (ABI) in the range of > 0.8 to < 1.1 or Tcpo2 > 40 mm Hg from the foot at the time of the initial allograft applicaton
  6. In subjects with multiple wounds only the largest wound receiving the allograft was included and considered the target wound
  7. Initial wound size >1 cm 2
  8. All wound locations within the lower extremity (defined as below the knee) and wound durations included
  9. Concomitant Negative pressure wound therapy was allowed as this could have been an anchoring technique for the allograft
  10. Concomitant antibiotics ( topical, oral, or intravenous) were allowed as it was not possible to determine whether administration of antibiotics was due to a true infection at the target wound site.

Exclusion Criteria:

  1. Wound etiologies other than diabetic neuropathy or nevous such as trauma, burns, sickle cell anemia, necrobiosis lipoidica , pyoderma gangrenosum.
  2. Wound not present for at least 30 days and showing lack of progression for at least 30 days prior to application of Theraskin.
  3. Other ulcer treatments besides study allograft during the study period ( study period definition: time of first allograft application up to 20 weeks) were not included in this study. These concomitant treatments specifically include hyperbaric oxygen treatments, venous ablation procedures, revascularization procedures including lower extremity bypass grafts or angioplasties or stents, application of additional growth factors, biologic products containing cells or other tissue-derived products, matrix components, or enzymatic debriders. Subjects were allowed to receive standard of care therapy with the study allograft, which included debridement, moist dressings or compression dressings depending on wound etiology, and off-weighting depending on wound location.
  4. Patients with revascularization procedures (defined as lower extremity bypass grafts, angioplasties, or stents) within 30 days of initial TheraSkin application were excluded
  5. Patients with successful surgical correction or intervention aimed at improving venous return in the target limb, such as venous ablation procedures, within 30 days of initial TheraSkin application were excluded

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03999281


Locations
Layout table for location information
United States, Virginia
Inova Fairfax Hospital
Fairfax, Virginia, United States, 22042
Sponsors and Collaborators
Solsys Medical LLC

Layout table for additonal information
Responsible Party: Solsys Medical LLC
ClinicalTrials.gov Identifier: NCT03999281     History of Changes
Other Study ID Numbers: SolubleS
First Posted: June 26, 2019    Key Record Dates
Last Update Posted: June 28, 2019
Last Verified: June 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No